AKT1 and non-small cell lung carcinoma: In the cohort of NSCLC patients studied here, AKT pathway is activated in 62% of cases, with significant S473 phosphorylation detected more frequently in patients with advanced disease (TNM stage III vs. stage II; n = 26; p<0.05) and higher grade (G3–G4 compared with G1–G2; n = 83; p<0.05).